All pricing and treatment details are reviewed during the consultation so patients can make an informed decision before starting

Patients undergoing tirzepatide therapy commonly experience: Improved blood pressure: reductions in systolic and diastolic blood pressure have been observed across tirzepatide clinical trials Better cholesterol profiles: reductions in LDL and triglycerides, with improvements in HDL Improved blood glucose regulation: tirzepatide significantly improves insulin sensitivity and reduces fasting glucose, even in patients without diabetes Reduction in waist circumference: visceral fat reduction, which is directly associated with reduced cardiovascular and metabolic risk Preservation of lean muscle mass: unlike traditional caloric restriction, which often results in 2530% of weight loss coming from muscle, tirzepatide promotes preferential fat loss Potential hormonal benefits: emerging evidence suggests that fat mass reduction lowers aromatase activity, which may support healthier testosterone-to-estrogen balance For patients managing multiple metabolic conditions simultaneously, GLP-1/GIP weight loss therapy represents an opportunity to address root causes, rather than individual symptoms, through a single medically supervised intervention

Lip C injections are not FDA-approved as standalone therapeutic agents
The research is based on shipment records of key ingredients from 2024 and 2025, and uses the same methodology that has been used in the past to accurately predict the prices of generic medicines for HIV, hepatitis C and some cancer drugs